Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 18/20 | 0.75 |
| ▸ | HTR2C | P28335 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | RAB9A | P51151 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10039646 | 0.95 | MCHR1 (0.68) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL12531391 | 0.94 | MCHR1 (0.67) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL12531387 | 0.94 | MCHR1 (0.67) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL10039400 | 0.94 | MCHR1 (0.67) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL6895401 | 0.93 | MCHR1 (0.70) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL6893838 | 0.92 | MCHR1 (0.72) | MCHR1HTR2CMEN1KMT2A | |
| SCHEMBL12543058 | 0.92 | MCHR1 (0.64) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL12531389 | 0.91 | MCHR1 (0.63) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL14970114 | 0.91 | MCHR1 (0.63) | MCHR1HTR2CMEN1KMT2ANPC1 | |
| SCHEMBL6926140 | 0.91 | MCHR1 (0.72) | MCHR1HTR2CMEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1100485-A4 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-06-09 | — | — | EP | claimed |
| JP-2002521436-A | — | — | 2002-07-16 | — | — | JP | claimed |
| EP-1100485-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006146-A9 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2000-08-03 | — | — | WO | claimed |
| WO-2000006146-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | claimed |
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | HAMMERSMITH IMANET LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| EP-1100485-A4 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-06-09 | — | — | EP | disclosed |
| EP-1100485-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006146-A9 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2000-08-03 | — | — | WO | disclosed |
| WO-2000006146-A1 | SUBSTITUTED ANILIDE COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130129625-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | MCHR1 74/4885HTR2C 1744/4885MEN1 1111/4885 |
| US-20130129626-A1 | IN VIVO IMAGING AGENTS | CCR5, CCR2, CX3CR1 | MCHR1 74/4885HTR2C 1744/4885MEN1 1111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.